m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00430)
Name
AZ12260493
Synonyms
AZ 12260493; AZ-12260493
    Click to Show/Hide
Status
Investigative
Structure
Formula
C24H29N3O3S
InChI
1S/C24H29N3O3S/c1-24(2,3)27-23(28)21(22(31(27,29)30)18-10-6-4-7-11-18)25-19-12-14-20(15-13-19)26-16-8-5-9-17-26/h4,6-7,10-15,25H,5,8-9,16-17H2,1-3H3
InChIKey
IVANYIPLGFVBGR-UHFFFAOYSA-N
PubChem CID
11655079
TTD Drug ID
D03YUL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Oxysterols receptor LXR-alpha (NR1H3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for AZ12260493. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of AZ12260493 through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). [1], [2]
References
Ref 1 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021 Jan 8;12(1):177. doi: 10.1038/s41467-020-20379-7.
Ref 2 An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31. doi: 10.1038/383728a0.